Results 41 to 50 of about 24,646 (191)

Fondaparinux versus Enoxaparina no Tratamento de Pacientes Obesos com Síndrome Coronariana Aguda [PDF]

Arquivos Brasileiros de Cardiologia
Resumo Fundamento: O fondaparinux é um anticoagulante eficaz e seguro usado no tratamento de síndromes coronarianas agudas (SCAs). No entanto, devido à baixa representatividade de indivíduos obesos em ensaios clínicos, os efeitos de se aplicar os ...
Beatriz Rocha Darzé, Carolina Costa da Silva Souza, Queila Borges de Oliveira, João Victor Santos Pereira Ramos, Mateus S. Viana, Eduardo Sahade Darzé, Luiz Eduardo Fonteles Ritt   +6 more
doaj   +1 more source

Monitoring the appropriate prescription of low molecular weight heparins and Fondaparinux through administrative data. A retrospective observational study in the Tuscany region.

PLoS ONE, 2023
IntroductionLow Molecular Weight Heparins (LMWHs) and Fondaparinux have been widely used as anticoagulants. Mass prescription may lead to prescriptive inappropriateness, which causes Heparin-induced thrombocytopenia and other side effects.ObjectivesThe ...
Giaele Moretti, Bruna Vinci, Simona Zito, Alessia Caputo, Francesco Attanasio, Milena Vainieri   +5 more
doaj   +1 more source

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis

, 2007
No data about the use of the pentasaccharide fondaparinux, a highly selective indirect inhibitor of factor Xa, in patients treated with haemodialysis are available.
Aregger, Fabienne, Kalicki, Robert, Frey, Felix J, Uehlinger, Dominik E, Alberio, Lorenzo, Lämmle, Bernhard   +5 more
core   +1 more source

Prophylactic Enoxaparin Reduces Symptomatic Venous Thromboembolism Compared With No Chemoprophylaxis Within 95 Days After Knee Arthroscopy

Arthroscopy, EarlyView.
Purpose To investigate whether prophylactic use of low‐molecular‐weight heparin (enoxaparin) after knee arthroscopy reduces the incidence of symptomatic venous thromboembolism (VTE) compared with no postoperative pharmacological prophylaxis. Methods We conducted a population‐based cohort study using linked national insurance and hospital data from ...
Aylin Albrecht, Lorenz Kapral, Felix Gruber, Christoph Dibiasi, Oliver Kimberger, Christian Albrecht   +5 more
wiley   +1 more source

Comparison of fondaparinux and enoxaparin in acute coronary syndromes [PDF]

, 2019
Background: the combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would
Esplugas Oliveras, Enrique, The OASIS-5 committee   +1 more
core   +2 more sources

Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol

BMC Pharmacology and Toxicology, 2023
Plain Language Summary New Fondaparinux Protocol to Reduce the Risk of Blood Thickening and Blood Clots Formation in Adults with Kidney Disease and Heparin-induced Thrombocytopenia (drop in platelets after the use of heparin): A Test Study.
Dania Ghaziri, Hassan Dehaini, Mayyas Msheik, Marwan Bahmad, Maya Zorkot, George Abi Saad   +5 more
doaj   +1 more source

Low-Molecular-Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study

Medicina, 2022
Background and objectives: Cementless total hip arthroplasty is a common surgical procedure and perioperative thromboprophylaxis is used to prevent deep vein thrombosis or pulmonary embolism.
Dragos Apostu, Bianca Berechet, Daniel Oltean-Dan, Alexandru Mester, Bobe Petrushev, Catalin Popa, Madalina Luciana Gherman, Adrian Bogdan Tigu, Ciprian Ionut Tomuleasa, Lucian Barbu-Tudoran, Horea Rares Ciprian Benea, Doina Piciu   +11 more
doaj   +1 more source

Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice

Journal of Hospital Medicine, EarlyView.
Abstract Background The American Society of Hematology (ASH) recommends assessing venous thromboembolism (VTE) and major bleeding risk to optimize pharmacological VTE prophylaxis for medical inpatients. However, the clinical utility of model‐guided approaches remains unknown.
Benjamin G Mittman, Michael B. Rothberg
wiley   +1 more source

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2020
Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Emily Bontekoe BS, Omer Iqbal MD, Walter Jeske PhD, Siddharth Mehrotra, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Jawed Fareed PhD   +8 more
doaj   +1 more source

Choosing Between Enoxaparin and Fondaparinux for the Prevention of Thromboembolism: A Meta-Analysis of Randomized Trials

Egyptian Journal of Critical Care Medicine, 2022
Background Venous thromboembolism (VTE), are few of the most serious complications in ICU. There are Pharmacological and mechanical prophylaxis methods are used to reduce the risk of thromboembolism and the most efficient is the pharmacological methods ...
Enas W. Mahdy, Ahmed Mostafa Abd El-Hamid, Reham Mahmoud Shady, Basem Mofreh Aglan   +3 more
doaj   +1 more source